Primary series in individuals age 6 months and older, or as a booster dose in individuals age 12 years and older: The Moderna Spikevax®Monovalent COVID-19 vaccine(Omicron XBB.1.5 subvariant) is approved for people who are 6 months of age and older. It may be given to people who have been previously vaccinated or who have not been previously vaccinated.

Your province or territory decides when people receive their doses of the vaccine. These decisions are based on public health recommendations and the latest evidence. The National Advisory Committee on Immunization (NACI) recommends an mRNA vaccine (Pfizer-BioNTech Comirnaty ® or Moderna Spikevax ®) should be offered for your second dose.The mRNA sequence from Moderna Spikevax ® COVID-19 vaccine is also included in the Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1). The bivalent booster also has an additional mRNA sequence that targets the Omicron BA.1 variant. The safety and effectiveness of the Moderna Spikevax® Monovalent COVID-19 vaccine (Omicron XBB 1.5) is based on studies of Spikevax® (Original, Original/Omicron BA.1 & XBB.1.5). Dosage Primary series The Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.1) is approved as a booster for people who are 6 years of age and older. Its safety and effectiveness in younger people has not yet been established. Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) months to 4 years (25 micrograms at least 6 months after their previous dose). If the child has not been previously vaccinated, Spikevax XBB.1.5 should be administered a 2-dose regimen. Health care providers must report possible reactions following vaccination to their local public health authority. The public health authority then reports them to the Public Health Agency of Canada.

After getting vaccinated, it's common to have temporary side effects. These can last a few hours to a few days after vaccination.A different vaccine may be offered for your second dose. For example, you may have received Pfizer-BioNTech Comirnaty ® as your first dose and be offered Moderna Spikevax ® as your second. This is known as a mixed vaccine series. The Moderna Spikevax ® COVID-19 vaccine is approved for primary vaccination in people who are 6 months of age and older. Its safety and effectiveness in people younger than 6 months have not yet been established. This vaccine is also approved as a booster for people 12 years of age and older. Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1) The Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1) was shown to increase the immune response against the Omicron BA.1 variant. This means that the booster is expected to offer protection against this variant. Reported allergic reactions and side effects to COVID-19 vaccines are published weekly in our Reported side effects following COVID-19 vaccination report. Vaccine review, approval and monitoring The bivalent Original/Omicron BA.1 0.1 mg/mL multi-dose vial has a royal blue plastic cap and green label.